Bicycle Therapeutics wheels in $201.3m growth capital


Transatlantic biotech game-changer Bicycle Therapeutics is wowing NASDAQ with its 12-month performance and fundraising magic.

Based at the Babraham Research Campus in Cambridge and Massachusetts in the US, the company has just closed a placement of American Depositary Shares which brought in gross proceeds of $201.3 million.

Goldman Sachs & Co. LLC, Morgan Stanley and SVB Leerink acted as joint book-running managers for the offering. JMP Securities acted as co-manager.

Bicycle Therapeutics is pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology.
In the last 12 months, the company’s NASDAQ share price has increased 105 per cent while revenue has grown by 31 per cent.

Published on: 22.10.21

Article sourced from